In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.

doi:10.1158/1078-0432.CCR-20-3237

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2021

Malla Sudhir B, Fisher David J, Domingo Enric, Blake Andrew, Hassanieh Sylvana, Redmond Keara L, Richman Susan D, Youdell Michael, Walker Steven M, Logan Gemma E, Chatzipli Aikaterina, Amirkhah Raheleh, Humphries Matthew P, Craig Stephanie G, McDermott Ultan, Seymour Matthew T, Morton Dion G, Quirke Philip, West Nicholas P, Salto-Tellez Manuel, Kennedy Richard D, Johnston Patrick G, Tomlinson Ian, Koelzer Viktor H, Campo Letitia, Kaplan Richard S, Longley Daniel B, Lawler Mark, Maughan Timothy S, Brown Louise C, Dunne Philip D

Abstract excerpt

PURPOSE: The DNA damage immune response (DDIR) assay was developed in breast cancer based on biology associated with deficiencies in homologous recombination and Fanconi anemia pathways. A positive DDIR call identifies patients likely to respond to platinum-based chemotherapies in breast and esophageal cancers. In colorectal cancer, there is currently no biomarker to predict response to oxaliplatin. We tested the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Assay

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Fluorouracil

Share to Leucovorin

Share to Neoadjuvant Therapy

Share to Organoplatinum Compounds

Share to Progression-Free Survival

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 33028592
DOI: 10.1158/1078-0432.CCR-20-3237
PMCID: PMC7614625

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.PMID 33028592Read ↗

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint InhibitorsSemantic proximity Read ↗

Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer.Semantic proximity Read ↗

Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic ImplicationsSemantic proximity Read ↗

Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.Semantic proximity Read ↗

DNA Damage and Repair Biomarkers of Immunotherapy ResponseSemantic proximity Read ↗

The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer.Semantic proximity Read ↗

Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.Semantic proximity Read ↗

DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errorsSemantic proximity Read ↗

Identification of DNA Repair-related Genes as Biomarkers Reflecting MSI, TMB, and TIL in Colorectal Cancer.Semantic proximity Read ↗

Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal CancerSemantic proximity Read ↗

Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy.Semantic proximity Read ↗

Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.